Communiqués Merck & Co., Inc. London S.E.

Actions

0QAH

US58933Y1055

Temps réel estimé Tradegate Autres places de cotation 10:53:58 03/07/2024			Varia. 5j.	Varia. 1 janv.
119,5 ^EUR	0,00%		+2,60%	0,00%

01/07	Merck et Orion convertissent leur collaboration en cours en une licence mondiale exclusive pour l'opevesostat	MT
01/07	Merck : accord de licence avec Orion Corp. pour opevesostat	CF

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer	02/07	AQ
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer	01/07	BU
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30	01/07	BU
CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE for Pneumococcal Vaccination in Appropriate Adults	28/06	AQ
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC	28/06	AQ
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	28/06	AQ
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)	28/06	BU
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults	28/06	BU
Merck : CDC’s ACIP Unanimously Votes to Add Merck and Sanofi’s Pediatric Hexavalent Combination Vaccine to its Preferential Recommendation to Help Prevent Invasive Hib Disease in American Indian and Alaska Native Infants - Merck.com	27/06	PU
Merck - Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/06	AQ
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/06	BU
USDA Approves Merck Animal Health's NOBIVAC NXT Canine Flu H3N2, The First and Only RNA-Particle Technology Vaccine for Canine Influenza	26/06	AQ
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza	25/06	BU
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	18/06	AQ
FDA Approves Merck s KEYTRUDA plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma	18/06	AQ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	17/06	BU
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma	17/06	BU
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05/06	BU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Anaveon announces IND approval of ANV600-001 Phase I/II clinical study	30/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Merck & Co., Inc. : Une vache à lait qui cache des vedettes

Le 11 juillet 2022 à 11:12